Related Experiment Videos
Use of amiodarone in the postmyocardial infarction patient
E Ozdil1, T A Carlson, A Massumi
1Department of Adult Cardiology, Texas Heart Institute, Houston 77030, USA.
Insights
Amiodarone effectively reduces mortality in post-myocardial infarction patients with ventricular ectopic activity. Despite previous concerns, this antiarrhythmic agent shows promise for improving survival in these high-risk individuals.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Ventricular ectopic activity (VEA) is an adverse prognostic factor post-myocardial infarction (MI).
- VEA was initially considered a consequence of myocardial damage but is now recognized as an independent mortality risk factor.
- Previous practice favored treating asymptomatic VEA post-MI, a strategy largely abandoned after the Cardiac Arrhythmia Suppression Trial (CAST).
Purpose of the Study:
- To review the pharmacology of amiodarone.
- To discuss clinical trial results regarding amiodarone's efficacy in post-MI patients.
- To explore amiodarone's role in improving survival in post-MI patients with VEA.
Main Methods:
- Review of amiodarone's pharmacological properties.
- Analysis of relevant clinical trial data, including post-CAST studies.
- Discussion of ongoing large, multicenter trials.
Main Results:
- Amiodarone demonstrates effectiveness in reducing mortality in post-MI patients with VEA.
- The Cardiac Arrhythmia Suppression Trial (CAST) significantly altered treatment paradigms for VEA.
- Emerging evidence suggests amiodarone improves survival in the post-MI population.
Conclusions:
- Amiodarone is a promising antiarrhythmic agent for post-myocardial infarction patients.
- Further research through ongoing trials is needed to fully elucidate amiodarone's benefits and optimal use.
- Current data support amiodarone's potential role in improving outcomes for patients with ventricular arrhythmias post-MI.
Abstract:
Amiodarone appears to be an effective antiarrhythmic agent for reducing mortality in the postmyocardial infarction patient with ventricular ectopic activity. Such activity has long been recognized to have an adverse effect on prognosis after acute myocardial infarction. When a strong correlation between ectopic activity and left ventricular dysfunction was demonstrated, ventricular ectopic activity was thought to be a consequence of underlying myocardial damage. However, ventricular ectopic activity is now considered to be an independent risk factor for mortality after myocardial infarction. Because of the basic premise that a positive correlation existed between arrhythmia suppression and improved survival, it had been common practice to use antiarrhythmic agents to treat asymptomatic ventricular ectopic activity in the postinfarction patient. After the results of the Cardiac Arrhythmia Suppression Trial (CAST) were released, this practice was largely abandoned. In the post-CAST era, however, amiodarone has appeared to improve survival in patients who have sustained myocardial infarctions. In this report, we briefly review the pharmacology of amiodarone and discuss the results of relevant clinical trials. Large, multicenter trials currently under way may clarify some of the unanswered questions surrounding the use of this promising antiarrhythmic agent in postmyocardial infarction patients.